Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 16:05 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
January 10, 2022 06:59 ET
|
Century Therapeutics, Inc.
- Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development - - First...
Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:30 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Added to the NASDAQ Biotechnology Index
December 17, 2021 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates
December 16, 2021 06:30 ET
|
Century Therapeutics, Inc.
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of...
Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021 07:30 ET
|
Century Therapeutics, Inc.
Lead program, CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the...
Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update
November 04, 2021 09:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering
October 07, 2021 07:30 ET
|
Century Therapeutics, Inc.
Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to...
Century Therapeutics Announces Its Addition to the Russell 2000® Index
September 17, 2021 16:01 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...